Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 12/20 | 0.60 |
| ▸ | PDGFRA | P16234 | 11/20 | 0.60 |
| ▸ | BCR | P11274 | 8/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.60 |
| ▸ | PRKCA | P17252 | 3/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | KIT | P10721 | 5/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | ABL2 | P42684 | 2/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12987337 | 0.93 | PDGFRA (0.63) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL15654456 | 0.89 | PDGFRA (0.61) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL15653665 | 0.87 | PDGFRA (0.62) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL12987184 | 0.85 | ABL1 (0.59) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL12987530 | 0.84 | ABL1 (0.58) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL15653668 | 0.81 | PDGFRA (0.54) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL3048286 | 0.80 | PDGFRA (0.73) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL18210972 | 0.78 | ABL1 (0.69) | ABL1PDGFRABCRPDGFRBEGFR | |
| Iodide SCHEMBL15632994 | 0.78 | ABL1 (0.69) | ABL1PDGFRABCRPDGFRBEGFR | |
| Iodide SCHEMBL15632996 | 0.78 | ABL1 (0.69) | ABL1PDGFRABCRPDGFRBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359376-B2 | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds | SPHAERA PHARMA PTE. LTD (SG) | 2016-06-07 | — | — | US | claimed |
| US-20140121367-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | PIVOT HOLDING LLC | 2014-05-01 | — | — | US | claimed |
| EP-2693876-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | Sphaera Pharma Pte. Ltd (SG) | 2014-02-12 | — | — | EP | claimed |
| WO-2012137225-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | SPHAERA PHARMA PVT. LTD (IN) | 2012-10-11 | — | — | WO | claimed |
| US-9359376-B2 | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds | SPHAERA PHARMA PTE. LTD (SG) | 2016-06-07 | — | — | US | disclosed |
| US-20140121367-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | PIVOT HOLDING LLC | 2014-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121367-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | TPMT, BHMT2, PFAS | ABL1 2560/4885PDGFRA 1970/4885BCR 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.